Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) missed Wall Street’s revenue expectations in Q4 CY2024, but ...

Strategic Financial Concepts LLC acquired a new stake in shares of NeoGenomics, Inc. (NASDAQ:NEO – Free Report) during the 4th quarter, according to its most recent filing with the SEC. The ...

Q4 2024 Earnings Call Transcript February 18, 2025 NeoGenomics, Inc. beats earnings expectations. Reported EPS is $0.04, ...

Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) will be reporting results tomorrow morning. Here’s what to ...

What Happened? Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) fell 21.5% in the afternoon session ...

NeoGenomics (NASDAQ:NEO – Get Free Report) had its price objective decreased by analysts at Needham & Company LLC from $19.00 to $18.00 in a report released on Wednesday,Benzinga reports.

NeoGenomics (NASDAQ:NEO – Get Free Report) had its target price reduced by Bank of America from $19.00 to $16.00 in a research note issued on Wednesday,Benzinga reports.The brokerage currently ...

NeoGenomics, Inc. (NASDAQ:NEO – Get Free Report) hit a new 52-week low during mid-day trading on Tuesday after the company announced weaker than expected quarterly earnings.The company traded as ...

Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on NeoGenomics (NASDAQ:NEO) in the last three months. The table below provides a snapshot of ...